Quantcast Mohamed Industry News
mohamed industry news By
mohamed industry news >> CANCER September 01, 2014 members login here
>>  CANCER
[Articles] Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO):
Lancet Oncology - 90 Minutes ago
Findings from the randomised phase 3 NeoALTTO trial in women with HER2-positive early breast cancer showed that the combination of lapatinib and trastuzumab significantly improved rates of pathological
[Comment] Dual targeting of HER2 with lapatinib and trastuzumab Lancet Oncology
all 1 news articles >>      Add Comment

AID induces intraclonal diversity and genomic damage in CD86+ cells in chronic lymphocytic
European Journal of Immunology - 34 Minutes ago
The activation-induced cytidine deaminase (AID) mediates somatic hypermutation and class switch recombination of the immunoglobulin (Ig) genes by directly deaminating cytosines to uracils. As AID causes
     Add Comment

Securing sustainable research: Peter Mac cancer experts awarded prestigious five-year
Noodls - 45 Minutes ago
The future of some of the Peter MacCallum Cancer Centre's most innovative laboratory and pathology re projects received a major boost on Friday afternoon when the Federal Minister for Health, the Hon.
     Add Comment

Renal Cell Carcinoma Market Analysis & Epidemiology Forecast to 2023 Says a New
WVNS - 4 Hours ago
This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith. SOURCE: MarketOptimizer.org adds EpiCast Report Renal
Renal Cell Carcinoma Market Analysis & Epidemiology Forecast to... PRWeb
all 1 news articles >>      Add Comment

Proof that the proton cancer cure Ashya's parents were fighting for CAN save lives
NewsRT.co.uk - 69 Minutes ago
Lucy Thomas is a bright, energetic, little girl, who's excited about starting year four at school this week. So it's hard to believe that just two years ago, she was battling cancer. At the age of six,
     Add Comment

01:18 Scottish cutting edge cancer treatment girl dies
NewsRT.co.uk - 86 Minutes ago
A TEENAGER who campaigned to raise awareness about childhood cancer, and made history when she received gene therapy for her terminal tumour, has died. Erin Griffin, 14, and her family emigrated from
     Add Comment

[Personal View] Statins and breast cancer prognosis: evidence and opportunities
Lancet Oncology - 90 Minutes ago
Much preclinical and epidemiological evidence supports the anticancer effects of statins. Epidemiological evidence does not suggest an association between statin use and reduced incidence of breast cancer,
     Add Comment

[Review] Guidance on the management of diarrhoea during cancer chemotherapy
Lancet Oncology - 90 Minutes ago
Diarrhoea induced by chemotherapy in cancer patients is common, causes notable morbidity and mortality, and is managed inconsistently. Previous management guidelines were based on poor evidence and neglect
     Add Comment

[Articles] Integrated collaborative care for major depression comorbid with a poor
Lancet Oncology - 90 Minutes ago
The management of depression in patients with poor prognosis cancers, such as lung cancer, creates specific challenges. We aimed to assess the efficacy of an integrated treatment programme for major depression
     Add Comment

[Articles] Effect of enzalutamide on time to first skeletal-related event, pain,
Lancet Oncology - 90 Minutes ago
In the AFFIRM trial of patients with metastatic castration-resistant prostate cancer after progression with docetaxel treatment, enzalutamide significantly increased overall survival compared with placebo.
     Add Comment

[Articles] Fertility preservation for girls and young women with cancer: population-based
Lancet Oncology - 90 Minutes ago
Ovarian tissue cryopreservation with later reimplantation has been shown to preserve fertility in adult women, but this approach remains unproven and experimental in children and adolescents. We aimed
     Add Comment

[Articles] Safety and activity of alectinib against systemic disease and brain metastases
Lancet Oncology - 90 Minutes ago
Patients with non-small-cell lung cancer (NSCLC) and ALK rearrangements generally have a progression-free survival of 8—11 months while on treatment with the ALK inhibitor crizotinib. However, resistance
     Add Comment

[Articles] Active monitoring, radical prostatectomy, or radiotherapy for localised
Lancet Oncology - 90 Minutes ago
Prostate cancer is a major public health problem with considerable uncertainties about the effectiveness of population screening and treatment options. We report the study design, participant sociodemographic
     Add Comment

[Articles] Safety and activity of ibrutinib plus rituximab for patients with high-risk
Lancet Oncology - 90 Minutes ago
Ibrutinib, an orally administered covalent inhibitor of Bruton's tyrosine kinase (BTK), is an effective treatment for relapsed chronic lymphocytic leukaemia (CLL). We investigated the activity and safety
     Add Comment

[Articles] Short-term androgen suppression and radiotherapy versus intermediate-term
Lancet Oncology - 90 Minutes ago
We investigated whether 18 months of androgen suppression plus radiotherapy, with or without 18 months of zoledronic acid, is more effective than 6 months of neoadjuvant androgen suppression plus radiotherapy
     Add Comment

[Articles] FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line
Lancet Oncology - 90 Minutes ago
Cetuximab and bevacizumab have both been shown to improve outcomes in patients with metastatic colorectal cancer when added to chemotherapy regimens; however, their comparative effectiveness when partnered
     Add Comment

[Cancer and Society] Life improving on art: paediatric cancer on film
Lancet Oncology - 90 Minutes ago
If you develop childhood cancer in a film, your prospects are appalling: mortality in the movies is 66%, despite the fact that if you escaped into the real world, your chances of survival would increase
     Add Comment

[Cancer and Society] Breast cancer: finding the silver lining in a dark cloud
Lancet Oncology - 90 Minutes ago
Copyright © 2014 Elsevier Limited except certain content provided by third parties. The Lancet® is a registered trademark of Reed Elsevier Properties S.A., used under licence The Lancet.com website is
     Add Comment

[Cancer and Society] Friendship overcomes cancer
Lancet Oncology - 90 Minutes ago
“This is the worst thing that will happen to us in our entire lives”, Zoe is convinced when she and her best friend Olivia are kicked out of a prestigious New York ballet school. However, it soon becomes
     Add Comment

[Cancer and Society] Systemic anti-cancer therapy (SACT) dataset
Lancet Oncology - 90 Minutes ago
, all NHS trusts in England that deliver systemic anti-cancer therapy ( SACT ) are required to provide comprehensive monthly usage data to the Chemotherapy Intelligence Unit (established and hosted by
     Add Comment

[Cancer and Society] Life's lessons, scantly observed
Lancet Oncology - 90 Minutes ago
Wish I Was Here is director, writer, and star Zach Braff's follow up to the 2004 indie hit Garden State . The two films share a lot, and not just in the presence of Braff. Both films focus myopically
     Add Comment

[Cancer and Society] Music against cancer
Lancet Oncology - 90 Minutes ago
Sex, drugs, and rock and roll. Live fast, die young. The rock and heavy metal community is traditionally associated with hedonism and reckless living; rarely thought of as being concerned about health
     Add Comment

[Cancer and Society] Electrotherapy: enlightening modern medicine
Lancet Oncology - 90 Minutes ago
Electrical power is a fundamental requirement of our daily lives. But beyond its use for work and play, what do we know about using electricity to treat our medical ailments? Electrotherapy, the application
     Add Comment

[News] Flexible sigmoidoscopy screening for colorectal cancer
Lancet Oncology - 90 Minutes ago
A new study has reaffirmed the value of flexible sigmoidoscopy screening for colorectal cancer. The trial randomly assigned roughly 100 000 individuals aged 50—64 years taken directly from the Norwegian
     Add Comment

[News] Osteosarcoma survivors' risk of second cancer
Lancet Oncology - 90 Minutes ago
New research suggests that survivors of osteosarcoma have a substantially increased risk of developing secondary malignant neoplasms (SMNs) compared with the general population; worryingly, patients treated
     Add Comment

Already a member? Sign in
Email Address:
Password:
Forget your password?

Build a News Circle   |   Get News Briefings   |   Congoo News Home   |   Get the Netpass
About Congoo   |   Terms of Use   |   Privacy Policy   |   Need Help?   |   Site Map
Copyright ©2014 Congoo.com. All Rights Reserved.